Giada Crescioli

Dr. Giada Crescioli

University of Florence - Department of Neuroscience, Psychology, Drug Research and Child Health
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2018 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
Giada CrescioliGiada Crescioli
Giada Crescioli
NLNiccolò Lombardi
Niccolò Lombardi
ABAlessandra Bettiol
Alessandra Bettiol
EMEttore Marconi
Ettore Marconi
FRFilippo Risaliti
Filippo Risaliti
Alfredo VannacciAlfredo Vannacci
Alfredo Vannacci

22 December 2017 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ARAnna Rosati
Anna Rosati
LILucrezia Ilvento
Lucrezia Ilvento
Ersilia LucenteforteErsilia Lucenteforte
Ersilia Lucenteforte
APAlessandra Pugi
Alessandra Pugi
Giada CrescioliGiada Crescioli
Giada Crescioli
RGRenzo Guerrini
Renzo Guerrini

16 April 2018 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
Niccolò LombardiNiccolò Lombardi
Niccolò Lombardi
Giada CrescioliGiada Crescioli
Giada Crescioli
ABAlessandra Bettiol
Alessandra Bettiol
EMEttore Marconi
Ettore Marconi
Antonio VitielloAntonio Vitiello
Antonio Vitiello
Alfredo VannacciAlfredo Vannacci
Alfredo Vannacci
To describe frequency, preventability and seriousness of adverse drug reactions (ADRs) in children as cause of emergency department (ED) admission and to evaluate the association between specific factors and the reporting of ADRs. A retrospective analysis based on reports of suspected ADRs collected between January 1st, 2012 and December 31st, 2016 in the ED of Meyer Children’s Hospital (Italy). Demographics, clinical status, suspected drugs, ADR description, and its degree of seriousness were collected. Logistic regression was used to estimate the reporting odds ratios (RORs) with 95% confidence intervals (CIs) of potential predictors of ADR seriousness. Within 5 years, we observed 834 ADRs (1100 drug-ADR pairs), of whom 239 were serious; of them, 224 led to hospitalization. Patients were mostly treated with one drug. Among patients treated with more than one drug, 78 ADRs presented a potential interaction. The most frequently reported ADRs involved gastrointestinal system. The most frequently reported medication class was antinfectives. Risk of serious ADR was significantly lower in children and infants compared to adolescents (ROR 0.41 [95% CI: 0.27–0.61] and 0.47 [0.32–0.71], respectively), and it was significantly increased in subjects exposed to more than one drug (ROR 1.87 [1.33–2.62] and 3.01 [2.07–4.37] for subjects exposed to 2 and 3 or more drugs, respectively). Gender, interactions and off-label drug use did not influence the risk of serious ADRs. Active surveillance in pharmacovigilance might represent the best strategy to estimate and characterize the clinical burden of ADRs in children.

Verified
Journal Article
Open access
PDF file
SPSilvia Pagani
Silvia Pagani
Niccolò LombardiNiccolò Lombardi
Niccolò Lombardi
Giada CrescioliGiada Crescioli
Giada Crescioli
VVVioletta Giuditta Vighi
Violetta Giuditta Vighi
GSGiulia Spada
Giulia Spada
OGon behalf of the MEREAFaPS Study Group
on behalf of the MEREAFaPS Study Group
The aim of the present study is to describe pharmacological characteristics of drug-related allergies and anaphylaxis leading to the emergency department (ED). An 8-year post hoc analysis on the MEREAFaPS Study database was performed (2012–2019). Subjects who experienced drug-related hypersensitivity leading to an ED visit were selected. Logistic regression analyses were used to estimate the reporting odds ratios (RORs) of drug-related allergies and anaphylaxis adjusting for sex, age classes, and ethnicity. In addition, a systematic review of observational studies evaluating drug-related hypersensitivity reactions leading to ED visits in outpatients was performed. Out of 94,073 ED visits, 14.4% cases were drug-related allergies and 0.6% were anaphylaxis. Females accounted for 56%. Multivariate logistic regression showed a higher risk of drug-related allergy among males and all age classes < 65 years, while a higher risk of anaphylaxis was observed for females (ROR 1.20 [1.01–1.42]) and adults (ROR 2.63 [2.21–3.14]). The systematic review included 37 studies. ED visits related to allergy and anaphylaxis ranged from 0.004% to 88%, and drug-related allergies and anaphylaxis ranged from 0.007% to 88%. Both in our analysis and in primary studies, antibacterials, analgesics, and radiocontrast agents were identified as the most common triggers of hypersensitivity.

24 January 2020 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
Niccolò LombardiNiccolò Lombardi
Niccolò Lombardi
ABAlessandra Bettiol
Alessandra Bettiol
Giada CrescioliGiada Crescioli
Giada Crescioli
VMValentina Maggini
Valentina Maggini
EGEugenia Gallo
Eugenia Gallo
FFFabio Firenzuoli
Fabio Firenzuoli
Introduction: Products containing anthraquinones (AQ) are mainly used as laxatives and have several biological effects. Long-term use of AQ laxatives is associated with an increased risk of serious adverse events (AEs), such as colorectal cancer (CRC). We will systematically synthesize the evidence on the potential association between the use of AQ laxatives and the risk of CRC. Methods and analysis: We will search MEDLINE, Embase, Scopus, the Cochrane Library, Google Scholar, and Clinicaltrials.gov. To avoid missing any relevant studies, we will search the bibliographies of retrieved papers and recent reviews in the field. Interventions will include products containing oral AQ laxatives, in particular, those derived from rhubarb, senna, cascara, buckhorn, and aloe. Two review authors will independently screen title, abstract, and full texts and will independently extract data from included studies. The primary outcome is the number of participants diagnosed with CRC, while the secondary outcome will be cases of melanosis coli. We will also consider all other AEs reported in the included studies, in particular, intestinal bleeding, alterations of gastrointestinal motility, and potential for dependence. When possible and appropriate, for each outcome, a meta-analysis will be performed. Discussion: This protocol is prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines. The protocol gives an insight into the scope and parameters for the systematic review to be carried out. Systematic review registration: PROSPERO CRD42019125414

16 May 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
ABAlessandra Bettiol
Alessandra Bettiol
Niccolò LombardiNiccolò Lombardi
Niccolò Lombardi
EMEttore Marconi
Ettore Marconi
Giada CrescioliGiada Crescioli
Giada Crescioli
RBROBERTO BONAIUTI
ROBERTO BONAIUTI
Alfredo VannacciAlfredo Vannacci
Alfredo Vannacci
Aims: The use of complementary and alternative medicines (CAMs) during breastfeeding is increasing, mainly because of their presumed greater safety compared with conventional medications. However, CAMs can cause serious adverse effects, and there is limited high‐quality evidence supporting their use during lactation. In Italy, specific investigations on the attitude of lactating women towards CAMs are lacking. The Herbal supplements in Breastfeeding InvesTigation (HaBIT) study aimed to explore attitudes to and knowledge on CAMs among lactating women.Methods: A web‐based survey was conducted over a 6‐year period among lactating women resident in Tuscany, Italy. Data on lactating behaviour, CAMs use during pregnancy or breastfeeding, and women's knowledge about the efficacy and safety of CAMs were collected.Results: A total of 388 lactating women answered the questionnaire. The majority of them were primiparae, with a high educational level. Of these, 204 women declared themselves to have used CAMs during breastfeeding. Moreover, 61% and 48% of subjects reported also using CAMs before and during pregnancy, respectively. A significant proportion of subjects were unable to identify correctly the types of CAMs they were using. Seventy‐three per cent of women were convinced that CAMs were equally safe or safer than conventional medications; nevertheless, 65% of women admitted to have no scientific information about the potential risks of CAMs, and 14 CAMs users reported that they had experienced side effects.Conclusions: These results demonstrate the need for healthcare providers to increase the awareness of breastfeeding women about CAMs. Further research is needed to support the evidence base for nonpharmaceutical approaches for symptom control during breastfeeding.